Cargando…

Effect of time and titer in convalescent plasma therapy for COVID-19

The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Candia, Paola, Prattichizzo, Francesco, Garavelli, Silvia, La Grotta, Rosalba, De Rosa, Annunziata, Pontarelli, Agostina, Parrella, Roberto, Ceriello, Antonio, Matarese, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297982/ https://www.ncbi.nlm.nih.gov/pubmed/34316549 http://dx.doi.org/10.1016/j.isci.2021.102898

Ejemplares similares

T Cells: Warriors of SARS-CoV-2 Infection
por: de Candia, Paola, et al.
Publicado: (2021)

The pleiotropic roles of leptin in metabolism, immunity, and cancer
por: de Candia, Paola, et al.
Publicado: (2021)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
por: La Grotta, Rosalba, et al.
Publicado: (2022)

CD4(+) T-Cell Activation Prompts Suppressive Function by Extracellular Vesicle-Associated MicroRNAs
por: Di Silvestre, Dario, et al.
Publicado: (2021)

One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study
por: La Sala, Lucia, et al.
Publicado: (2020)

Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms
por: Sardu, Celestino, et al.
Publicado: (2022)

Type 2 Diabetes: How Much of an Autoimmune Disease?
por: de Candia, Paola, et al.
Publicado: (2019)

Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity
por: Garavelli, Silvia, et al.
Publicado: (2020)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Tackling the pillars of ageing to fight COVID-19
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

A unique plasma microRNA profile defines type 2 diabetes progression
por: de Candia, Paola, et al.
Publicado: (2017)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
por: Cacciapuoti, Sara, et al.
Publicado: (2020)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2023)

The Multifaceted Interface Between Cytokines and microRNAs: An Ancient Mechanism to Regulate the Good and the Bad of Inflammation
por: Garavelli, Silvia, et al.
Publicado: (2018)

Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19
por: Fazeli, Alieh, et al.
Publicado: (2022)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2022)

SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
por: D'Onofrio, Nunzia, et al.
Publicado: (2023)

Extracellular vesicles circulating in young organisms promote healthy longevity
por: Prattichizzo, Francesco, et al.
Publicado: (2019)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
por: Wardhani, Shinta Oktya, et al.
Publicado: (2021)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma
por: Sanfilippo, Filippo, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
por: McDyer, John F., et al.
Publicado: (2023)

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
por: Kasten, Mary J., et al.
Publicado: (2023)

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
por: Gordon, Oren, et al.
Publicado: (2022)

Pharmacological management of COVID-19 in type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2021)

Variability of risk factors and diabetes complications
por: Ceriello, Antonio, et al.
Publicado: (2021)

Metabolism and Autoimmune Responses: The microRNA Connection
por: Colamatteo, Alessandra, et al.
Publicado: (2019)

Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D
por: La Sala, Lucia, et al.
Publicado: (2019)

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
por: Donato, Michele L., et al.
Publicado: (2021)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Gontu, Abhinay, et al.
Publicado: (2021)

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
por: Herman, Jonathan D., et al.
Publicado: (2021)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lp9iqm1nr9hmbhcuurq77jtr33